MedTrace Logo

Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine

NCT00210288 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2018-08-08

No results posted yet for this study

Summary

The purpose of this study is to assess the immune response produced by two doses of SC599 vaccine compared to placebo.

Conditions

  • Shigella Infection

Interventions

BIOLOGICAL

SC599

Sponsors & Collaborators

  • Institut Pasteur

    lead INDUSTRY

Principal Investigators

  • Dr Odile Launay, MD · Hôpital Cochin - Bâtiment Modulaire, France

  • Dr David Lewis, MD · St George's Hospital Vaccine Institute, UK

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2006-09-30
Completion
2007-04-30

Countries

  • France
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00210288 on ClinicalTrials.gov